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cal treatment of retroperitoneal lymph nodes in patients with
testicular cancer is made quite firmly including a comment
relating to combination chemotherapy that 'azoospermia
appears to persist for years if not permanently.' Elsewhere in
the volume however it is noted that 'Retrospective review of
a group of 28 patients indicated normal sperm counts in 46%
of patients after chemotherapy.' These differences of view
serve only to emphasise the problems which currently still
face the profession as does the statement in relation to
exenteration that, 'at the start of the operative procedure the
para-aortic nodes are palpated and any enlarged nodes
submitted for frozen section histology.' It is noted that
'metastatic disease in the para-aortic nodes is an absolute
contraindication to pelvic exenteration.' Nonetheless, 'formal
para-aortic lymphadenectomy is advised in the absence of
suspicious lymph nodes.' If the whole operation is pointless
in the presence of metastases it hardly seems necessary to do
the resection if metastases are absent. Perhaps this will be
clarified in a further edition.
There is a similar inconsistency in considering the follow
up of transitional cell tumours of the bladder where it is
noted that 'Among the 600 patients with transitional cell
carcinoma of the bladder, 4% developed upper tract lesions
after a delay of approximately 61 months.' The subsequent
advice is to have an annual radiological examination of the
upper tract for 2 years after initial diagnosis and treatment of
either an upper tract or bladder transitional cell carcinoma.
This seems inconsistent if most ofthe upper tract occurrences
in those treated for bladder carcinoma will occur subsequent
to 2 years.
It is always possible to find inconsistencies in any work of
reference and I have mentioned those which I have found,
merely to draw attention to the fact that I have read every
page of this book with interest and enjoyment. Each chapter
is well written and beautifully illustrated, whilst the sections
towards the end of the book dealing with the current know-
ledge concerning the possibilities for chemotherapy in each
group of tumours, the possible role of radiation therapy,
imaging techniques, tips on intestinal and vascular surgery
and observations upon medical evaluation, nutritional and
metabolic care, psychosexual support and care for the ter-
minally ill patient are thoughtful and most relevant additions
to a surgical text.
In my view, every department of urology should have two
copies of this book, one in its departmental library and the
other immediately available in the operating suite so that it
may be consulted at any time before or during an operation
for cancer of the urinary tract.
Philip H. Smith
Immunosuppression and Human Malignancy
Edited by D. Naor, B.Y. Klein, N. Tarcic and J.S. Duke-
Cohan, Clifton, New Jersey: Humana Press, 1990, 271 pp.
£59.10.
Our understanding of the relationship between immune
status and malignancy has a long and somewhat controver-
sial history. At one extreme of this controversy, immuno-
logical deficits are held to be intimately connected with
progression of malignant disease; others have dismissed any
immunological defects that may be found as post hoc pheno-
mena, a consequence of malignant disease rather than a
necessary precursor of it. The field is also complicated by the
range of (not easily reproducible) in vitro techniques that
have been used to define immunological defects and to probe
their mechanistic basis. To this one can add the basic
dilemma posed by insufficient knowledge of the in vivo role
both of the effector cell types being studied and their putative
regulatory mechanisms. For example, the regulation of
natural killer (NK) cell activity by monocytes begs the ques-
tions of whether NK cell activity is relevant to the develop-
ment of malignancy, and if it is, whether NK activity is
regulated by monocytes in vivo.
The authors are fully aware of these dilemmas, and they
seek to avoid them by providing a very comprehensive
assessment of the widest possible range of candidate regu-
latory and suppressive mechanisms that could influence the
growth of malignant tumours. Whilst this detailed scholar-
ship is an admirable summation of these possible mechan-
isms, in the process the major disadvantage of this book
quickly becomes apparent. The problem is that the majority
of the book appears to have been written in 1984-5, with a
few later additions in early 1987. In many fields, this delay
would not vitiate the endeavour, but immunology is develop-
ing rapidly, and particularly within the last 3-4 years when
several fundamental conceptual advances have occurred. The
most notable is probably the Bjorkman model for the struc-
ture of MHC antigens, with consequences for the nature ofT
cell recognition and the mechanisms of antigen processing,
transport and presentation. Another development that is now
more widely recognised is that of antigen processing by B
lymphocytes. The earlier explanation of cognate help which
involved antigen forming a bridge between receptors of T
and B cells is alluded to in the introduction to the chapter on
suppressor cells and human malignancy. The current view is
that the B cell receptor allows preferential uptake of native
antigen which is processed, followed by presentation of
associated T cell epitope(s) to CD4 T cells in the context of
the B cell's class II MHC.
As well as producing rapid developments in some areas,
immunologists also have a remarkable capacity to lose faith
(or at least lose interest) in others. As briefly discussed at the
end of the concluding chapter of the book, suppressor cells
are very much in the latter category. The current lack of
willingness on the part of some investigators to countenance
a major in vivo role for suppressor cells, whether or not as a
distinct functional population of cells, may subsequently
prove to be an extreme view, but it contrasts very strongly
with the zeitgeist so apparent in the earlier chapters of the
book.
One is left with the feeling that whilst the detailed discus-
sions of suppressor mechanisms developed in the book are
valid within their own terms of reference, time has moved on
too far and too fast for these considerations to have a major
impact on current thinking in this area, and necessarily limits
the value of the book even to a more general readership.
R.A. Robins
Programmed Cell Death in Tumours and Tissues
I.D. Bowen and S.M. Bowen, London: Chapman & Hall,
1990, 276 pp. £38.00.
The renaissance of interest in programmed cell death in
tumours, after a relatively low key burst of excitement in the
topic in the early 1970's, has been driven to a large degree by
the application of molecular biological techniques to this
fascinating topic. A review of the subject is therefore most
welcome. The Bowens' book has been expertly timed: it
precedes the publication of a Cold Spring Harbor publication
on programmed cell death by a few months. When CSH
publishes a monograph (after holding a meeting last Spring)
it suggests that programmed cell death has come of age!
How does a cell die? Bowen and Bowen give us plenty of
descriptions in their book: death by cell deletion, by necrosis,
apoptosis (programmed cell death), accidental cell death,
induced cell death, death by differentiation and death by
autolysis. Each of these definitions attempts to clarify the
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murder. Undoubtedly, the task of trying to create order from
this semantic jungle is an extremely difficult one for the
authors, but the thermodynamic differences which delineate
programmed cell death from necrosis surely lie at the centre
of this tangled mass: programmed cell death is initially uphill
and necrosis downhill. So, whilst the book serves as a basic
introduction to this exciting area, it did not clarify for this
reader whether some of these various descriptions of cell
death are really just semantic delineations, or whether there
are many ways that a cell can die, uphill or down. For
example, in discussing apoptosis as defined by Wyllie and
colleagues, it is stated that '(their) description ofapoptosis ...
is not applicable to all systems. Specialised cells in both
plants and animals can differentiate to death along specific
pathways' (page 31). But how do these differentiated cells
die? Recent reports on the fate of human neutrophils suggest
that their fate certainly is apoptosis. And this make sense: the
uncontrolled breakdown of this differentiated cell so as to
release its armory of lytic enzymes would be a disaster for
the host. Perhaps the detailed accounts of the Bowens' own
research (rather parochially described at times), on the role
of degradative enzymes in programmed cell death, presented
a counter-intuitive slant to the description of a controlled,
uphill process driven by the early activation of new gene
expression.
After a brief introduction to the concept of programmed
cell death in the first chapter the authors move on to the
mechanistic aspects. Some recent examples of the temporal
sequence of events which initiate programmed cell death
attempt counterbalance their bias towards the role of lytic
hydrolases and phosphatases. However, it is a shame that the
central role of calcium as a signal which might initiate gene
transcription necessary for programmed cell death is not
tackled in any depth, and the paradox of a calcium signal in
thymocytes triggering the opposing processes of mitosis and
apoptosis is not discussed, despite the elegant studies of
Orrenius and colleagues who have tried to tackle this prob-
lem. The same type of paradox arises in the observations of
Lockshin and coworkers that the activation of the transcrip-
tional cascade c-fos - c-myc - hsp 70 is conserved between
mitosis and the castration-induced programmed cell death
observed in the rat ventral prostate; their work is not referred
to. I was eager to read how the authors, who have been in
the vanguard of those studying cell death, might interpret
current puzzles of these types. It is in these very fields of
signalling and changes in gene expression that progress is
likely to be made in our understanding of mechanisms
initiating and controlling programmed cell death and this is
where all the excitement is at present. The beautiful work of
Horvitz and his colleagues on the identification of the genes
ced-3 and ced-4, which are responsible for the patterns of
programmed cell death in C.elegans, is not discussed, and no
reference is made to the expression of TRPM-2 gene which is
a programmed cell death-associated gene expressed in the
prostate. This is a shame because it places the book amongst
earlier monographs which have, necessarily, focussed on the
histopathology of cell death rather than its mechanics, and
this old-fashioned approach greatly diminishes the impact of
the book and its timeliness.
The style of the text suggests that it is targeted to the final
year undergraduate or first year postgraduate and much of
the areas reviewed might be valuable to a novice in the field,
despite caveats regarding style and specific content. The
authors include an appendix of methodology, which reflects
further their prejudices as to the importance of phosphatases
in programmed cell death. It is surprising that they do not
include a discussion of the problems of detecting the apop-
totic cell nor any methodological hints on assaying an impor-
tant biochemical marker of apoptosis, the induction of inter-
nucleosomal strand breaks in DNA. Inside the book there is
definitely another book struggling to be born, the germ of
which is very well written in comparison to much of the rest;
this is on the mode of action of cytokines and it forms
almost half of the text. If this was given less prominence and
the emerging biochemical and molecular biological aspects of
programmed cell death were reviewed in detail, a rigorously
edited book would have more appeal.
J.A. Hickman